Company intelligence / Profile preview

RetMap

Chicago, Illinois, United Statesretmapinc.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

The company’s flagship product, the RM Electrode®, has received FDA clearance. It enables improved sensitivity in electroretinography testing for early detection of neurodegenerative eye diseases that can cause irreversible blindness. Clinical validation and adoption are supported by key opinion leaders in ophthalmology.

No published clinical trial results were found; the focus appears to be on commercial deployment of an approved device.

Therapeutic areas: Ophthalmology
Modalities: Device (specifically electroretinography diagnostic device)
Industry: Physiological Monitoring

Partnerships

Collaborations with academic institutions such as University of Illinois at Chicago for technology development

Beyond the preview

Go deeper on RetMap.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetMap.

Explore the full profile